Livio Trusolino

Citata da

	Tutte	Dal 2020
Citazioni	23272	11177
Indice H	71	50
i10-index	120	97

2300

1150

575

1725

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202558 79 80 146 185 202 227 232 249 263 268 406 442 574 679 875 1015 1205 1450 1404 1735 1937 2286 2267 2198 2159 320

Accesso pubblico

Visualizza tutto

85 articoli

2 articoli

Disponibili

Non disponibili

In base ai mandati di finanziamento

Coautori

Andrea BertottiUniversity of Torino - School of MedicineEmail verificata su ircc.it
francesco sassiIRCC-University of Torino School of Medicine, Laboratory of Molecular Pharmacology ItalyEmail verificata su ircc.it
Enzo MedicoProfessor of Histology, University of Torino and Head of the Laboratory of Oncogenomics, CandioloEmail verificata su ircc.it
Salvatore SienaUniversità degli Studi di Milano e Ospedale Niguarda, Milano, ItalyEmail verificata su unimi.it
Claudio IsellaIRCCEmail verificata su ircc.it
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - ItalyEmail verificata su ospedaleniguarda.it
Luca LazzariIFOM - FIRC Institute of Molecular OncologyEmail verificata su ifom.eu
Fortunato CiardielloProfessore di oncologia medica, seconda università di napoliEmail verificata su unina2.it
Jos JonkersProfessor at Leiden University and group leader at Netherlands Cancer Institute, Oncode InstituteEmail verificata su nki.nl
Simona CorsoUniversity of TorinoEmail verificata su ircc.it
Alessandro AMOREOspedale Regina Margherita Torino, Università degli studi TorinoEmail verificata su unito.it
Lorenzo CapussottiChief of the Surgical Deparment- Ospedale Mauriziano "Umberto I" TorinoEmail verificata su mauriziano.it
Charlotte RolnyAssociate professor of tumor biology, PI at Lund University and Karolinska Institutet, SwedenEmail verificata su med.lu.se
Guido SeriniProfessor, University of Torino School of Medicine | Candiolo Cancer Institute IRCCSEmail verificata su ircc.it
Dario RiberoDirigente Medico I livello, Divisione di Chirurgia Generale ed Oncologica, Ospedale Mauriziano Umberto IEmail verificata su mauriziano.it
Massimiliano MazzoneGroup Leader, Vesalius Research CenterEmail verificata su vib-kuleuven.be
Andrea CasazzaDirector Biology @ Montis Bioscience, BelgiumEmail verificata su montisbio.com
Lodewyk WesselsProfessor of Computational Cancer BiologyEmail verificata su nki.nl
Giuseppe Bassoprofessor of pediatrics university paduaEmail verificata su unipd.it
Antonio PalumboUniversità di Torino; Torino ItalyEmail verificata su unito.it

Segui

Livio Trusolino

Professor, University of Torino School of Medicine, Italy

Email verificata su ircc.it - Home page

Targeted anti-cancer therapies animal models oncogenic signal transduction pathways


Titolo Ordina per citazioni Ordina per anno Ordina per titolo	Citata da Citata da	Anno
Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014	1779	2014
MET signalling: principles and functions in development, organ regeneration and cancer L Trusolino, A Bertotti, PM Comoglio Nature reviews Molecular cell biology 11 (12), 834-848, 2010	1390	2010
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019	1189	2019
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016	1051	2016
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011	1048	2011
Drug development of MET inhibitors: targeting oncogene addiction and expedience PM Comoglio, S Giordano, L Trusolino Nature reviews Drug discovery 7 (6), 504-516, 2008	983	2008
Scatter-factor and semaphorin receptors: cell signalling for invasive growth L Trusolino, PM Comoglio Nature reviews cancer 2 (4), 289-300, 2002	915	2002
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013	721	2013
Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017	720	2017
Stromal contribution to the colorectal cancer transcriptome C Isella, A Terrasi, SE Bellomo, C Petti, G Galatola, A Muratore, A Mellano, ... Nature genetics 47 (4), 312-319, 2015	672	2015
A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth L Trusolino, A Bertotti, PM Comoglio Cell 107 (5), 643-654, 2001	574	2001
The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015	494	2015
The Met tyrosine kinase receptor in development and cancer A Gentile, L Trusolino, PM Comoglio Cancer and metastasis reviews 27, 85-94, 2008	398	2008
Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019	388	2019
EGFR Blockade Reverts Resistance to KRAS^G12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020	369	2020
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014	359	2014
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy PM Comoglio, L Trusolino, C Boccaccio Nature Reviews Cancer 18 (6), 341-358, 2018	334	2018
Interactions between growth factor receptors and adhesion molecules: breaking the rules PM Comoglio, C Boccaccio, L Trusolino Current opinion in cell biology 15 (5), 565-571, 2003	326	2003
Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. G Tripodi, F Valtorta, L Torielli, E Chieregatti, S Salardi, L Trusolino, ... The Journal of clinical investigation 97 (12), 2815-2822, 1996	325	1996
HER2 activating mutations are targets for colorectal cancer treatment SM Kavuri, N Jain, F Galimi, F Cottino, SM Leto, G Migliardi, ... Cancer discovery 5 (8), 832-841, 2015	311	2015

Il sistema al momento non può eseguire l'operazione. Riprova più tardi.

Articoli 1–20

Citazioni per anno

Citazioni duplicate

Citazioni unite

Aggiungi coautoriCoautori

Segui

Citata da

Coautori